By proceeding, you agree to our Terms of Use and Privacy Policy.
The second edition of the industry-led Wet AMD & DME Drug Development Summit arrives in Boston to give you comprehensive insight into the current and emerging angiogenesis- inflammatory-directed and anti-fibrotic drug development programs for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD), diabetic retino
At the Wet AMD & DME Drug Development Summit hear from key Speakers working with Novartis Pharmaceuticals UK Ltd, Cleveland Clinic, Ocuphire, Isarna THerapeutics.
Three days of insightful talk, with two workshops will explore administration techniques, viral & non-viral vectors for effective anti-angiogenic eye therapies.
Forge meaningful connections with two whole dedicated hours of Networking with 80+ Industry Audience. Leverage the new trends in the wet AMD & DME field!
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Trial Runners is an ophthalmology CRO providing biotech and pharmaceutical companies with clinical research management services.
W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives.
Iveric Bio is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.
Experimentica Ltd. is a contract research organization dedicated to develop and provide ophthalmic models and our established methodologies in the field of neuroscience.
Icare Finland Oy is an advanced health technology company based in Vantaa, Finland. Company is a part of Revenio Group Corporation, a public company listed on the Helsinki Stock Exchange.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.